천장관절염 치료 시장 : 치료법별, 약제별, 진단별, 최종 사용자별, 국가별, 지역별 - 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Sacroiliitis Treatment Market size was valued at USD 2,360.1 Million in 2025, expanding to a CAGR of 6.6% from 2026 to 2033.

The sacroiliitis treatment include interventional procedures, physical therapies, and surgical solutions used to manage inflammation and pain affecting the sacroiliac joints. Nonsteroidal anti-inflammatory medications (NSAIDs), analgesics, corticosteroid injections, biologic therapy, and other treatments are available. Ankylosing spondylitis, psoriatic arthritis, axial spondyloarthritis, trauma, and other inflammatory diseases are associated to sacroiliitis.

Sacroiliitis Treatment Market- Market Dynamics

Growing prevalence of inflammatory & chronic musculoskeletal disorders and adoption of sacroiliac joint procedures are expected to propel market demand

The rising prevalence of inflammatory musculoskeletal disorders is a key factor driving the growth of the sacroiliitis treatment market. Sacroiliitis is commonly associated with inflammatory conditions such as axial spondyloarthritis, ankylosing spondylitis, and psoriatic arthritis, which can cause persistent pain, stiffness, and reduced mobility. The need for efficient treatments targeted at reducing inflammation and preserving joint function is growing as knowledge and diagnosis of these disorders advance. Particularly for individuals with moderate-to-severe inflammatory diseases, biologic treatments have grown in importance. TNF inhibitors like adalimumab, etanercept, infliximab, and golimumab, as well as IL-17 inhibitors like secukinumab and ixekizumab, are often utilized choices. In addition, growing physician awareness, advances in imaging and diagnostic techniques, and earlier identification of inflammatory sacroiliac joint disease are contributing to greater treatment adoption and supporting market growth.

The market for sacroiliitis treatments is expanding due in large part to the growing use of minimally invasive techniques. In order to attain longer-term pain alleviation and joint stabilization, patients with degenerative sacroiliitis or sacroiliac joint dysfunction who do not respond well to conservative therapy may have minimally invasive sacroiliac joint fusion. In order to support the sacroiliac joint while reducing tissue damage, blood loss, and recovery time, medical device manufacturers are developing implants and surgical techniques. While Medtronic provides the Rialto SI Fusion System for certain patients with degenerative sacroiliitis or SI joint disruption, SI-BONE's iFuse systems are specifically made for minimally invasive SI joint fusion. The use of minimally invasive surgery is being further supported by developments in porous titanium materials, smaller and anatomically tailored implants, image-guided navigation, and better surgical procedures.

Sacroiliitis Treatment Market- Segmentation Analysis:

The Global Sacroiliitis Treatment Market is segmented on the basis of Treatment Type, Medication Type, Diagnosis, End User, and Region.

The market is divided into five categories based on Treatment Type: medications, joint injections, radiofrequency ablation, sacroiliac joint fusion, and others. The medication segment held the large chunk of revenue in the treatment type. NSAIDs and analgesics medications are widely used to reduce pain and inflammation, while corticosteroids may be administered through local injections for targeted symptom relief. Patients with inflammatory sacroiliitis associated with axial spondyloarthritis may receive biologic therapies.

Sacroiliitis Treatment Market- Geographical Insights

North America holds a leading position in the sacroiliitis treatment market, supported by extensive use of biologic medicines, well-established rheumatology and pain management services, and robust presence of pharmaceutical and medical device companies. The United States remains a key market, driven by the availability of advanced inflammatory-disease treatments and increasing adoption of minimally invasive sacroiliac joint fusion procedures. Asia-Pacific is emerging as an attractive growth market, supported by improving healthcare infrastructure, rising healthcare expenditure, greater awareness of inflammatory musculoskeletal disorders, and expanding access to biologic therapies and advanced surgical treatments. China, Japan, India, South Korea, and Australia are among the key markets contributing to regional development. Latin America is expected to grow moderately during the forecast period.

UK Sacroiliitis Treatment Market- Key Insights

The UK has a substantial patient population affected by axial spondyloarthritis and other inflammatory conditions involving the sacroiliac joints. Treatment typically includes pharmacological therapies, physiotherapy, specialist rheumatology care, and biologic treatments for eligible patients with persistent or moderate-to-severe disease. Patients with inflammatory sacroiliac joint problems now have more therapy choices thanks to the increasing availability of targeted biologic treatments. For the treatment of axial inflammatory illnesses, TNF inhibitors and IL-17 inhibitors continue to be crucial therapeutic classes, especially for patients who do not respond well to traditional treatments. Additionally, the UK is a significant market for pharmaceutical research, clinical development, and the commercialization of cutting-edge treatments for inflammatory diseases. For example, UCB's BIMZELX (bimekizumab) has generated clinical evidence in axial spondyloarthritis, while other leading pharmaceutical companies continue to develop and commercialize targeted therapies aimed at improving outcomes for patients with inflammatory conditions.

Sacroiliitis Treatment Market- Competitive Landscape:

The market for sacroiliitis treatments is moderately competitive. By developing biologic medicines, targeted immunomodulators, biosimilars, increased therapeutic indications, clinical research, etc., major pharmaceutical companies are bolstering their position in the sacroiliitis treatment market. The market demand is being supplemented by the expanding development of targeted biologic medicines. Inflammatory sacroiliitis linked to axial spondyloarthritis and other inflammatory conditions can now be effectively treated with TNF inhibitors and IL-17 inhibitors. To increase efficacy, safety, and long-term illness control, businesses are funding clinical research and next-generation treatments. While promoting greater patient access to cutting-edge medicines, the growing availability of less expensive alternatives is escalating rivalry with well-established biologic medications.

Recent Developments:

In April 2025, Johnson & Johnson continued strengthening its immunology portfolio through the development of TREMFYA(R) (guselkumab). The company announced positive Phase 3b APEX trial results in patients with active psoriatic arthritis, highlighting improvements in clinical symptoms and the progression of structural joint damage.

In June 2025, UCB strengthened its position in inflammatory musculoskeletal disease by presenting three-year BIMZELX (bimekizumab) data at EULAR 2025 event, demonstrating sustained efficacy and long-term inflammation control in patients with axial spondyloarthritis.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SACROILIITIS TREATMENT MARKET KEY PLAYERS

• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• UCB SA
• Sandoz Group AG
• Samsung Bioepis Co., Ltd.
• Celltrion Healthcare Co., Ltd.
• Globus Medical, Inc.
• Orthofix Medical Inc.
• SI-BONE, Inc.
• Medtronic plc
• Others

GLOBAL SACROILIITIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020-2033

• Medications
• Joint injections
• Radiofrequency ablation
• Sacroiliac joint fusion
• Others

GLOBAL SACROILIITIS TREATMENT MARKET, BY MEDICATION TYPE- MARKET ANALYSIS, 2020-2033

• NSAIDs
• Analgesics
• Corticosteroids
• TNF Inhibitors
• Others

GLOBAL SACROILIITIS TREATMENT MARKET, BY DIAGNOSIS- MARKET ANALYSIS, 2020-2033

• Physical Examination
• X-ray
• Magnetic Resonance Imaging (MRI)
• Computed Tomography (CT)
• Others

GLOBAL SACROILIITIS TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2020-2033

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

GLOBAL SACROILIITIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020-2033

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Denmark
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Taiwan
• Vietnam
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Iran
• Qatar
• Rest of MEA

Table of Contents

1. Sacroiliitis Treatment Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Sacroiliitis Treatment Market Snippet by Treatment Type
  • 2.1.2. Sacroiliitis Treatment Market Snippet by Medication Type
  • 2.1.3. Sacroiliitis Treatment Market Snippet by Diagnosis
  • 2.1.4. Sacroiliitis Treatment Market Snippet by End User
  • 2.1.5. Sacroiliitis Treatment Market Snippet by Country
  • 2.1.6. Sacroiliitis Treatment Market Snippet by Region
• 2.2. Competitive Insights

3. Sacroiliitis Treatment Key Market Trends

• 3.1. Sacroiliitis Treatment Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Sacroiliitis Treatment Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Sacroiliitis Treatment Market Opportunities
• 3.4. Sacroiliitis Treatment Market Future Trends

4. Sacroiliitis Treatment Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Sacroiliitis Treatment Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Sacroiliitis Treatment Market Landscape

• 6.1. Sacroiliitis Treatment Market Share Analysis, 2025
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Sacroiliitis Treatment Market - By Treatment Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
  • 7.1.2. Medications
  • 7.1.3. Joint injections
  • 7.1.4. Radiofrequency ablation
  • 7.1.5. Sacroiliac joint fusion
  • 7.1.6. Others

8. Sacroiliitis Treatment Market - By Medication Type

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Medication Type, 2025 & 2033 (%)
  • 8.1.2. NSAIDs
  • 8.1.3. Analgesics
  • 8.1.4. Corticosteroids
  • 8.1.5. TNF Inhibitors
  • 8.1.6. Others

9. Sacroiliitis Treatment Market - By Diagnosis

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Diagnosis, 2025 & 2033 (%)
  • 9.1.2. Physical Examination
  • 9.1.3. X-ray
  • 9.1.4. Magnetic Resonance Imaging (MRI)
  • 9.1.5. Computed Tomography (CT)
  • 9.1.6. Others

10. Sacroiliitis Treatment Market - By End User

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
  • 10.1.2. Hospitals
  • 10.1.3. Specialty Clinics
  • 10.1.4. Ambulatory Surgical Centers
  • 10.1.5. Others

11. Sacroiliitis Treatment Market- By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. Sacroiliitis Treatment Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. Sacroiliitis Treatment Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.9. UK
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.9.4. UK Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.9.5. UK Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.10. France
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.10.4. France Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.10.5. France Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.11. Italy
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.11.4. Italy Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.11.5. Italy Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.12. Spain
    • 11.3.12.1. Overview
    • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.12.4. Spain Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.12.5. Spain Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.13. The Netherlands
    • 11.3.13.1. Overview
    • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.13.4. The Netherlands Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.13.5. The Netherlands Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Overview
    • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.15. Russia
    • 11.3.15.1. Overview
    • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.15.4. Russia Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.15.5. Russia Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.16. Poland
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.16.4. Poland Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.16.5. Poland Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.17. Rest of Europe
    • 11.3.17.1. Overview
    • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. Sacroiliitis Treatment Key Manufacturers in Asia Pacific
  • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  • 11.4.5. APAC Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
  • 11.4.6. APAC Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
  • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.8. China
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.8.4. China Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.4.8.5. China Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.9. India
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.9.4. India Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.4.9.5. India Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.13. Indonesia
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.13.4. Indonesia Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.4.13.5. Indonesia Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.14. Thailand
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.14.4. Thailand Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.4.14.5. Thailand Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.16. Rest of APAC
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.16.4. Rest of APAC Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.4.16.5. Rest of APAC Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.5. Latin America (LATAM)
  • 11.5.1. Overview
  • 11.5.2. Sacroiliitis Treatment Key Manufacturers in Latin America
  • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.5.4. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  • 11.5.5. LATAM Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
  • 11.5.6. LATAM Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
  • 11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.6. Middle East and Africa (MEA)
  • 11.6.1. Overview
  • 11.6.2. Sacroiliitis Treatment Key Manufacturers in Middle East and Africa
  • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  • 11.6.5. MEA Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
  • 11.6.6. MEA Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
  • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.14. Rest of MEA
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.14.4. Rest of MEA Market Size and Forecast, By Medication Type, 2020 - 2033 (US$ Million)
    • 11.6.14.5. Rest of MEA Market Size and Forecast, By Diagnosis, 2020 - 2033 (US$ Million)
    • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Sacroiliitis Treatment Industry

• 12.1. Competitive Dashboard
  • 12.1.1. Competitive Benchmarking
  • 12.1.2. Competitive Positioning
• 12.2. Company Profiles
  • 12.2.1. Pfizer Inc.
  • 12.2.2. Johnson & Johnson
  • 12.2.3. AbbVie Inc.
  • 12.2.4. Novartis AG
  • 12.2.5. Eli Lilly and Company
  • 12.2.6. Boehringer Ingelheim International GmbH
  • 12.2.7. Amgen Inc.
  • 12.2.8. UCB SA
  • 12.2.9. Sandoz Group AG
  • 12.2.10. Samsung Bioepis Co., Ltd.
  • 12.2.11. Celltrion Healthcare Co., Ltd.
  • 12.2.12. Globus Medical, Inc.
  • 12.2.13. Orthofix Medical Inc.
  • 12.2.14. SI-BONE, Inc.
  • 12.2.15. Medtronic plc
  • 12.2.16. Others

13. 360 Degree AnalystView

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us